Ablynx already rejected an offer by the Danish group on Dec. 14 and Novo Nordisk said the new bid, made on Dec. 22, was some 14 percent higher. The Belgian company was not immediately available for comment on Monday.
“Novo Nordisk regrets that the board of directors of Ablynx has so far declined to engage in any discussions, despite the proposals which have been put forward,” it said in a statement.
The Danish company said it would pay 28.00 euros per share in cash for Ablynx and an additional 2.50 euros per share if certain conditions related to its research portfolio were met.
Ablynx’s shares have almost doubled in price in the past 12 months, buoyed by successful medical trial data. They closed at 21.20 euros on Friday.
Ablynx specializes in researching novel drugs based on nano-bodies found in the immune systems of llamas and alpacas, for which it partners with several of the world’s largest pharmaceutical firms.
Its products, which are all still undergoing medical trials, target many different diseases such as rheumatoid arthritis, psoriasis or cancer.
An acquisition would be the first by Novo Nordisk CEO Lars Fruergaard Jorgensen, who took over a year ago. He has said the firm needs external innovation to broaden its product line-up.
Novo Nordisk, the world’s biggest diabetes company, has sat out a rash of deal-making that has gripped the rest of the drugs industry in recent years. It has instead focused on its market-leading position making insulin and other diabetes treatments.
In March, the company approached Global Blood Therapeutics (GBT.O), a U.S. biotechnology company focused on serious blood disorders, to discuss a potential takeover.
Tax breaks and other incentives have created a thriving biotech industry in Belgium, with many companies spun off from university projects now listed on the local stock exchange.
Last week, Japan’s Takeda (4502.T) bid 520 million euros for Belgian cell therapy group Tigenix. ($1 = 0.8322 euros)
By Robert-Jan Baratunek
Source: Reuters
In 2017, Sanofi partnered with the Lebanon, New Hampshire-based ImmuNext to develop an antibody for autoimmune diseases like lupus and multiple sclerosis, which included giving Sanofi a worldwide license to develop frexalimab. The agreement involved milestone payments upto $500 million.
Global manufacturer for the pharmaceutical, biotech and nutraceutical markets, Lonza has announced that it has acquired Synaffix, a biotech company focused on the commercialisation of its clinical stage technology platform for the development of antibody-drug conjugates (ADCs).
In its hunt for the new head of its pharmaceutical systems business—which makes syringes, self-injection systems and other drug delivery devices for 70% of the top 100 drugmakers in the world, according to the company—BD landed on a candidate with plenty of experience among that customer group.
